Hepatocyte Nuclear Factor-1α Recruits the Transcriptional Co-Activator p300 on the GLUT2 Gene Promoter
- Nobuhiro Ban13,
- Yuichiro Yamada1,
- Yoshimichi Someya1,
- Kazumasa Miyawaki1,
- Yu Ihara1,
- Masaya Hosokawa1,
- Shinya Toyokuni2,
- Kinsuke Tsuda13 and
- Yutaka Seino1
- 1Department of Metabolism and Clinical Nutrition, Graduate School of Medicine, Kyoto University, Japan
- 2Department of Pathology and Biology of Diseases, Graduate School of Medicine, Kyoto University, Japan
- 3Graduate School of Human and Environmental Studies, Kyoto University, Japan
Abstract
Mutations in the hepatocyte nuclear factor (HNF)-1α gene have been linked to subtype 3 of maturity-onset diabetes of the young (MODY), a disease characterized by a primary defect in insulin secretion. Here we show that the human GLUT2 gene is closely regulated by HNF-1α via sequences downstream of the transcriptional start site by interaction with transcriptional co-activator p300. The promoter region of the human GLUT2 gene was subcloned into luciferase expression plasmids that were transfected together with HNF-1α expression plasmid into a pancreatic β-cell line, HIT-T15, to evaluate transcriptional activities. HNF-1α enhanced human GLUT2 promoter activity sixfold. Site-direct mutagenesis and footprint analyses showed that the HNF-1α binding site (+200 to +218) is critical in human GLUT2 gene expression. Furthermore, mammalian two-hybrid and immunoprecipitation studies revealed the transactivation domain of HNF-1α (amino acids 391–540) to interact with both the NH2-terminal region (amino acids 180–662) and the COOH-terminal region (amino acids 1,818–2,079) of p300. These findings demonstrated that HNF-1α binds to the 5′-untranslated region of GLUT2 and that p300 acts as a transcriptional co-activator for HNF-1α. In addition, these results provided new insight into the regulatory function of HNF-1α by suggesting a molecular basis for human GLUT2 gene expression.
Footnotes
-
Address correspondence and reprint requests to Yutaka Seino, M.D., Ph.D., Department of Metabolism and Clinical Nutrition, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507 Japan. E-mail: seino{at}metab.kuhp.kyoto-u.ac.jp.
Received for publication 20 April 2001 and accepted in revised form 14 January 2002.
ABC, avidin-biotin complex; CBP, CREB-binding protein; CREB; DMEM, Dulbecco’s modified Eagle’s medium; EMSA, electrophoretic mobility shift assay; β-gal, β-galactosidase; GSIS, glucose-stimulated insulin secretion; GST, glutathione S-transferase; HAT, histone acetyltransferase; HNF, hepatocyte nuclear factor; MODY, maturity-onset diabetes of the young; P/CAF, p300/CBP-associated factor; PMSF, phenylmethylsulfonyl fluoride; SRC, steroid receptor co-activator; TBS, Tris-buffered saline; TBS-T, TBS containing 0.1% Tween-20; VP16, herpes virus acidic activation region.
- DIABETES














